Here’s whether Bristol-Myers Squibb Co. (BMY) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+1.05% over 10 days); strong 1-year return of +26.9%; 3-month momentum positive (+5.8%). Concerns: RSI 70 — overbought, elevated pullback risk. Currently 1.3% off its 52-week high. Score: +5/7.
BMY is in a confirmed uptrend, trading above both its 50-day ($57.45) and 200-day ($55.08) moving averages. With an RSI of 70.3, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +26.9% compares to +16.5% for SPY (beat the market by 10.4%).
$10,000 invested 1 year ago→ $12,687 today
vs. S&P 500 (SPY) — same period beat market by 10.4%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($55.08)
✓Above 50-day MA ($57.45)
!RSI(14) neutral zone (30–70) — currently 70.3
✓Positive return (+26.9%)
✓Within 10% of period high (−1.3%)
Period Range $62.09
$42.52$62.89
RSI (14) 70.3
0 · OversoldOverbought · 100
Key Metrics
Price$62.09
Period Return+26.9%
Period High$62.89
Period Low$42.52
Drawdown−1.3%
MA-50$57.45
MA-200$55.08
RSI (14)70.3
Avg Volume (30d)12.2M
vs. SPYbeat by 10.4%
Return Rank#321 of 999
Trend Signals
Price is above the 200-day moving average ($55.08)